Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection

Journal of Physiology and Pharmacology

Volumn 47, Issue 1, 1996, Pages 51-58

  Gabryelewicz, A ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b University Medical School   (Poland)

Author keywords

drug regimen; eradication; Helicobacter pylori (Hp); peptic ulcer

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE;

GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; REVIEW;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; PEPTIC ULCER; TETRACYCLINES; TINIDAZOLE;

EID: 0029981309     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-71.
2. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Ther 1995 Oct, 12: 984-991.
3. Cover TL, Blase MJ. Helicobacter pylori and gastroduodenal disease. Ann Rev Med 1992; 43: 135-145.
4. Valle J, Seppala K, Sipponen P, Kosunen T. Disappearance of gastritis after eradication of Helicobacter pylori: a morphometric study. Scand J Gastroenterol 1991: 26: 1057-1065.
5. Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nunulcer dyspepsia: a systematic overview. Can Med Assoc J 1994; 150: 177-185.
6. Van Deventer GM, Elashoff JD, Reedy TJ, Schneidman D, Walsh JH. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989; 320: 1113-1119.
7. Peterson WL, Barnett CC, Evans DJ Jr et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88: 2038-2043.
8. McColl KEL, Fullarton GM, Chittajalu R et al. Plasma gastrin daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 1991; 26: 339-346.
9. Montbriand JR, Appelman HD, Cotner EK, Nostrant TT, Elta GH. Treatment of Campylobacter pylori does not alter gastric acid secretion. Am J Gastroenterol 1989; 84: 1513-1516.
10. Graham DY, Opekun A, Lew GM, Klein PD, Walsh JH. Helicobacter pylori - associated exaggerated gastrin release in duodenal ulcer patients: the effect of bombesin infusion and urea ingestion. Gastroenterology 1991; 100: 1751-1755.
11. Isenberg JI, Selling JA, Hogan DL, Koss MA. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med 1987; 316: 374-379.
12. Cover TL, Halter SA, Blaser MJ. Characterisation of HeLa cell vacuoles induced by Helicobacter pylori broth culture supernatant. Hum Pathol 1992; 23: 1004-1010.
13. Burette A, Głupczynski Y, Deprez E. Evaluation of various multidrug eradication regiments for Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 817-823.
14. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727.
15. Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-363.
16. Penston J. G. Helicobacter pylori eradication - understandable caution but no excuse for inertia. Alimen Pharmacol Ther 1994; 8. 369-389.
17. Bell GD. Anti-Helicobacter pylori therapy: clearance, elimination, or eradication? Lancet 1991; 337: 310-311.
18. Graham DY, Klein PD, Evans DG et al. Simple noninvasive method for to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol 1991; 86: 1158-1162.
19. Grayson ML, Elioppoulus GM, Ferraro MJ, Moellering RC Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-889.
20. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. A Antimicrob Chemother 1992; 29: 115-120.
21. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-781.
22. Peterson WL, Graham DY, Marshall B et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860-1864.
23. Van Caekenberghe DL, Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother 1987; 31: 1429-1430.
24. Hosking SW, Ling TK, Yung MY et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ 1992; 305: 502-502.
25. Iwahi T, Satoh H, Nakao M et al. Lansoprazole a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 4: 697-702.
26. Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727.
27. Hunt RH. Helicobacter pylori eradication: a critical apprisal and current concerns. Scand J Gastroenterol 1995; 30 (Suppl 210): 73-76.
28. Weil J, Bel GD, Powell K et al. Helicobacter pylori infection treated with tripotassium dicitrato bismuthate and metronidazole combination. Aliment Pharmacol Ther 1990; 4: 651-657.
29. Bazzoli F, Gullini S, Zagari RM et al. Effect of omeprazole and clarithromycin plus tinidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. Gut 1995; 37 (Suppl. 1): 19.
30. Grasso GA, Battaglia G, Germana B et al. Efficacy of low doses of clarithromycin for one week in eradicating H. pylori. Gut 1995; 37 (Suppl. 1): A47.
31. Peterson W et al. and The Clarithromycin-Helicobacter pylori study group. Clarithromycin as monotherapy for eradication of Helicobacter pylori. Am J Gastroenterol 1992; 87: 1274.
32. Stupnicki Th, Taufer M, Denk H et al. Efficacy of triple therapy (sucralfate/amoxicillin/ metronidazole) in eradication of Helicobacter pylori and duodenal ulcer healing-follow-up to one year. Am J Gastroenterol 1994; 89: A1388.
33. Hu WHC. Omeprazole or sucralfate combined with clarithromycin and metronidazole in Helicobacter pylori eradication and ulcer healing. J Gastroenterol Hepatol 1994; 9. A11.
34. Slomiany BL, Slomiany A. Role of mucus in gastric mucosal protection. J Physiol Pharmacol 1991; 42: 149-163.
35. Slomiany BL, Murty VLN, Piotrowski J, Slomiany A. Gastroprotective agents in mucosal defence against H. pylori. Gen Pharmacol 1994; 25: 833-841.
36. Slomiany BL, Piotrowski J, Slomiany A. Effect of sucralfate on the degradation of human gastric mucus by H. pylori protease and lipase. Am J Gastroenterol 1992; 87: 595-599.
37. Slomiany BL, Murty VLN, Piotrowski J, Grabska M, Slomiany A. Glycosulftase activity of H. pylori toward human gastric mucin: effect of sucralfate. Am J Gastroenterol 1992; 87: 1132-1137.
38. Slomiany A, Piotrowski J, Slomiany BL. Sucralfate counteracts the inhibition of gastric mucosal mucin receptor by Helicobacter pylori lipopolysaccharide. Scand J Gastroenterol 1995; 30: 21, 77-81.
39. Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol 1995; (Suppl. 210): 82-84.
40. Kimura K, Ido K, Saifuku K et al. A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 60-63.
41. Tytgat GNJ, van Hulst J. Important acquistions in Helicobacter pylori infection. Curr Op Gastroenterol 1995; 11 (Suppl. 1): 57-60.
42. Bazzoli F, Zagari RM, Fossi S et al. Short - term, low dose triple therapy for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-776.
43. O'Morain C, Logan RPH and the Cloarithromycin European H, pylori Study Group. Clarithromycin (CL) in combination with omeprazole (OM) for healing of duodenal ulcers (DU), prevention of DU recurrence, and eradication of H. pylori (Hp) in two european studies. Gut 1995; 37 (Suppl. 1): A4.
44. Bardhan KD, Logan RPH, Celestin LR, Theodossi A, Palmer K, Reed PI. for the BHURG study. Clarithromycin (CL) and omeprazole (OM) in the prevention of duodenal ulcer (DU) recurrence and eradication of H. pylori (Hp). Gut 1995; 37 (Suppl. 1): A85.